Based on the data revealing a key role of SGLT1 transporter in increased intestinal glucose absorption and resulting hyperglycemia in diabetes, a new approach to reduce postprandial hyperglycemia using SGLT1 inhibitors seems promising for the treatment of diabetic patients [8,109]. Here, SLC5A1 is linked to diabetes mellitus.